Sublingual administration of furosemide: new application of an old drug
- PMID: 17875188
- PMCID: PMC2198789
- DOI: 10.1111/j.1365-2125.2007.03035.x
Sublingual administration of furosemide: new application of an old drug
Abstract
Background: In patients with decompensated heart failure, absorption of orally administered furosemide may be delayed, possibly leading to impaired pharmacodynamic effects. Sublingual administration may represent an alternative in such situations.
Methods: In a crossover study including 11 healthy men, 20 mg furosemide was administered intravenously, orally and sublingually on three different days. Pharmacokinetics and pharmacodynamics were assessed from repeated blood and urine samples.
Results: Compared with oral administration, sublingual administration was associated with 43% higher C(max)[difference 215 ng ml(-1), 95% confidence interval (CI) 37, 392], a higher urinary recovery (8.9 vs. 7.3 mg, difference 1.6 mg, 95% CI 0.3, 2.9), an 28% higher AUC (difference 328 ng h(-1) ml(-1), 95% CI 24, 632) and a higher bioavailability of furosemide (59 vs. 47%, difference 12.0%, 95% CI -1.2, 25.2). Sodium excretion was higher after sublingual compared with oral administration (peak excretion rate 1.8 vs. 1.4 mmol min(-1), P < 0.05), whereas urine volume did not differ significantly between the two application modes. In comparison, intravenous administration showed the expected more rapid and intense response.
Conclusion: Sublingually administered furosemide tablets differ in certain kinetic and dynamic properties from identical tablets given orally. Sublingual administration of furosemide may offer therapeutic advantages in certain groups of patients.
Figures












Similar articles
-
Variable furosemide absorption and poor predictability of response in elderly patients.Pharmacotherapy. 1997 Jan-Feb;17(1):98-106. Pharmacotherapy. 1997. PMID: 9017769 Clinical Trial.
-
[Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration].Arzneimittelforschung. 1982;32(12):1567-71. Arzneimittelforschung. 1982. PMID: 6891597 German.
-
Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.J Clin Pharmacol. 2003 Jul;43(7):711-20. J Clin Pharmacol. 2003. PMID: 12856384 Clinical Trial.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Pharmacokinetics of progesterone administered by the oral and parenteral routes.J Reprod Med. 1999 Feb;44(2 Suppl):141-7. J Reprod Med. 1999. PMID: 11392023 Review.
Cited by
-
Efficacy of Oral Furosemide Test for Primary Aldosteronism Diagnosis.J Endocr Soc. 2023 Nov 24;8(1):bvad147. doi: 10.1210/jendso/bvad147. eCollection 2023 Dec 1. J Endocr Soc. 2023. PMID: 38075562 Free PMC article.
-
Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.Eur J Clin Pharmacol. 2011 Jan;67(1):63-71. doi: 10.1007/s00228-010-0893-3. Epub 2010 Sep 21. Eur J Clin Pharmacol. 2011. PMID: 20857093 Clinical Trial.
-
Formulation of ketotifen fumarate fast-melt granulation sublingual tablet.AAPS PharmSciTech. 2010 Jun;11(2):679-85. doi: 10.1208/s12249-010-9425-9. Epub 2010 Apr 21. AAPS PharmSciTech. 2010. PMID: 20407934 Free PMC article.
-
Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system.Pflugers Arch. 2015 Dec;467(12):2413-21. doi: 10.1007/s00424-015-1714-4. Epub 2015 Jun 20. Pflugers Arch. 2015. PMID: 26089029 Clinical Trial.
-
Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and β-blockers - drug classes with low adherence in antihypertensive therapy.Sci Rep. 2019 Oct 30;9(1):15652. doi: 10.1038/s41598-019-52164-y. Sci Rep. 2019. PMID: 31666620 Free PMC article.
References
-
- Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–40. - PubMed
-
- Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs. 1985;30:427–43. - PubMed
-
- Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int. 1984;26:183–9. - PubMed
-
- Brater DC, Seiwell R, Anderson S, Burdette A, Dehmer GJ, Chennavasin P. Absorption and disposition of furosemide in congestive heart failure. Kidney Int. 1982;22:171–6. - PubMed
-
- Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous